Linezolid (WHOAPI-252) and Kanamycin (acid sulfate) (WHOAPI-257) manufactured by Zhejiang Hisun Pharmaceutical Co Ltd and ethambutol hydrochloride (WHOAPI-197) manufactured by Lupin Ltd (Ankleshwar) have been prequalified by the WHO Prequalification Team: medicines under its API prequalification procedure.
- WHOAPI-197 - Ethambutol hydrochloride - Lupin Ltd - INDIA
- FPPs containing ethambutol hydrochloride are used in the therapeutic area of tuberculosis
- WHOAPI-252 - Linezolid - Zhejiang Hisun Pharmaceutical Co Ltd - CHINA
- FPPs containing linezolid are used in the therapeutic area of tuberculosis
- WHOAPI-257 - Kanamycin (acid sulfate) - Zhejiang Hisun Pharmaceutical Co Ltd - CHINA
- FPPs containing kanamycin (acid sulfate) are used in the therapeutic area of tuberculosis
Good-quality APIs are vital to the production of good-quality medicines. WHO prequalification of APIs facilitates production of quality medicines by identifying such APIs for use by manufacturers of finished pharmaceutical products (FPPs).
API prequalification consists of a comprehensive evaluation procedure that has two components: assessment of the API master file (APIMF) to verify compliance with WHO norms and standards, and evaluation of the sites of API manufacture to verify compliance with WHO Good Manufacturing Practice requirements.
|手机版|蒲公英|ouryao|蒲公英
( 京ICP备14042168号-1 ) 增值电信业务经营许可证编号：京B2-20243455 互联网药品信息服务资格证书编号：(京)-非经营性-2024-0033
发表于 2018-6-29 19:09:02
置顶卡
变色卡
楼主